Investors

    NASDAQ: STEM

      Listed on the NASDAQ Market since 1992, we are committed to       balancing our standards of scientific rigor and clinical integrity with our       corporate imperatives of value creation and long-term business       sustainability.

Corporate Profile

Driven by nearly 20 years of pioneering research and innovation, StemCells, Inc. is at the forefront of a breakthrough approach to treating human disease. We are applying our scientific and industry leadership in stem cell biology to discover, develop and commercialize novel therapeutics and enabling tools and technologies for use in stem cell-based research and drug discovery.
More >>

Learn more about What Sets Us Apart.


StemCells, Inc. has been listed on the NASDAQ Market since 1992.
CEO Podcast
11/19/10  Interview with CEO Martin McGlynn on Proposed Spinal Cord Injury Trial
Letter to Investors
January 2014  Letter to Investors from CEO Martin McGlynn
Recent News
04/17/14StemCells, Inc. Completes Enrollment in Spinal Cord Injury Trial
Interim Data to be Presented at Upcoming American Spinal Injury Association Conference NEWARK, Calif., April 17, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that it has completed enrollment in the Company's Phase I/II clinical trial in spinal cord injury. The multi-national, open-label, Phase I/II trial is evaluating both safety and preliminary efficacy of StemCells, Inc.'s proprietary HuCNS-SC® human neural stem cells as a treatment for chronic spinal cord injury. Th... 
Printer Friendly Version
03/19/14StemCells, Inc. to Participate at the 13th Annual Needham Healthcare Conference
Management Will Present an Update on the Company's Programs, Pipeline and Operations NEWARK, Calif., March 19, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that management will present at the 13th Annual Needham Healthcare Conference, on Wednesday, April 9, at 8:40 AM EDT at the Westin Grand Central Hotel, 212 East 42nd Street, in New York City. Management is scheduled to present an update on the Company's programs, pipeline and operations. A live webcast of the pr... 
Printer Friendly Version
03/12/14StemCells, Inc. Reports Fourth Quarter and Full Year 2013 Financial Results and Provides Business Update
Conference Call to be Hosted March 12, 2014 at 4:30 p.m. EDT NEWARK, Calif., March 12, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2013. "2013 was a year of significant clinical and regulatory progress for StemCel... 
Printer Friendly Version
03/10/14StemCells, Inc. to Participate at 2014 Regen Med Investor Day in New York
President and CEO Martin McGlynn Will Present an Update on the Company's Programs, Pipeline and Operations NEWARK, Calif., March 10, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that Martin McGlynn will present at the 2nd Annual Regen Med Investor Day, Wednesday, March 26, 2014, at 3:30 pm EDT at the Metropolitan Club, One East 60th Street, in New York City. Mr. McGlynn is scheduled to present an update on the Company's programs, pipeline and operations. Organized ... 
Printer Friendly Version
More >>
Upcoming Events
There are currently no events scheduled.
More >>
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever StemCells, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
Enter your e-mail address here:

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
Stock Quote
STEM (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$1.25
Change (%) Stock is Up 0.02 (1.63%)
Volume323,320
Data as of 04/17/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Analyst Coverage

Click here for a list of analysts covering StemCells, Inc.

Primary IR Contact

Greg Schiffman
CFO
StemCells, Inc.
7707 Gateway Blvd
Newark, CA 94560
Phone: 510.456.4128
Fax: 650.475.3101
Contact by e-mail



Investor Tools
Print PagePrint Page
E-mail PageE-mail Page
RSS FeedsRSS Feeds
E-mail AlertsE-mail Alerts
Financial Tear SheetFinancial Tear Sheet